Secondary Logo

Journal Logo

January 2004 - Volume 32 - Issue 1
pp: 1-325

Administration of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote the resolution of shock in patients with severe sepsis: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*

Bakker, Jan; Grover, Robert; McLuckie, Angela; More

Critical Care Medicine. 32(1):1-12, January 2004.

Cardiovascular effects of the nitric oxide synthase inhibitor NG-methyl-l-arginine hydrochloride (546C88) in patients with septic shock: Results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-002)*

Watson, David; Grover, Robert; Anzueto, Antonio; More

Critical Care Medicine. 32(1):13-20, January 2004.

Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

López, Angel; Lorente, Jose Angel; Steingrub, Jay; More

Critical Care Medicine. 32(1):21-30, January 2004.









Guidelines for critical care medicine training and continuing medical education

Dorman, Todd; Angood, Peter B.; Angus, Derek C.; More

Critical Care Medicine. 32(1):263-272, January 2004.





The author replies:

Miller, Helen C.; Carney, Nancy A.; Chesnut, Randall M.; More

Critical Care Medicine. 32(1):310, January 2004.

Show: